An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
M. Degardin(Centre Hospitalier Universitaire de Nantes), P Cappelaere(European Organisation for Research and Treatment of Cancer), P. Fargeot(European Organisation for Research and Treatment of Cancer), P. Armand(European Organisation for Research and Treatment of Cancer), Patricia Tresca(Pierre Fabre (France)), J. Boudillet(Pierre Fabre (France)), Joana Oliveira(Universidade do Porto), J Chauvergne(European Organisation for Research and Treatment of Cancer), M. van Glabbeke(Institut Jules Bordet), L. Geoffrois(Centre Hospitalier Universitaire de Nantes), M.A. Lentz, P Bastit(European Organisation for Research and Treatment of Cancer), F. Rolland(Institut de Cancérologie de l'Ouest), P. Fumoleau(Institut Curie)
Cited by 38
Related Papers
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
|Journal of Clinical Oncology|2005|421
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
|Journal of Clinical Oncology|2010|401
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290